Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.

Abstract: A method for displaying location-specific content via a head-mounted display device includes: receiving, by the head-mounted display device, the location-specific content, wherein the location-specific content is related to a predetermined spatial position; determining, by the head-mounted display device, a distance between the head-mounted display device and the predetermined spatial position; and displaying, by the head-mounted display device, the location-specific content based on the determined distance between the head-mounted display device and the predetermined spatial position.

Abstract: A system for reproducing first reproduction data and for reproducing second reproduction data includes: a first reproduction device, configured for reproducing the first reproduction data; and a second reproduction device, configured for reproducing the second reproduction data. The system is configured such that the first reproduction data is transmitted to the first reproduction device via a first logical communication channel and the second reproduction data is transmitted to the second reproduction device via a second logical communication channel. The second logical communication channel is different from the first logical communication channel. The system is configured such that the first reproduction data is identified using pattern recognition, and determination of the second reproduction data is based on the identification of the first reproduction data.

Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.

Abstract: A method for preventing fraud or misuse based on a risk scoring approach when using a service of a service provider requested by a user equipment includes: in connection with a first occurrence of providing the service, the service provider transmits a request message to a subscriber database, the request message being related to the MSISDN of the user equipment, and the request message requesting additional data related to the user equipment and/or the subscriber identity module; the service provider receives an answer message from the subscriber database, the answer message comprising the additional data; and in connection with a second occurrence of providing the service, an authentication information is transmitted between the service provider and the user equipment without transmitting a request message and a corresponding answer message.

Abstract: The present invention relates to a method for thinning fruit by using the active substance metamitron and corresponding metamitron-containing fruit thinning formulations.

Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.

Abstract: The present invention relates to a method for thinning fruit by using the active substance metamitron and corresponding metamitron-containing fruit thinning formulations.

Abstract: A system for reproducing first reproduction data and for reproducing second reproduction data includes: a first reproduction device, configured for reproducing the first reproduction data; and a second reproduction device, configured for reproducing the second reproduction data. The system is configured such that the first reproduction data is transmitted to the first reproduction device via a first logical communication channel and the second reproduction data is transmitted to the second reproduction device via a second logical communication channel. The second logical communication channel is different from the first logical communication channel. The system is configured such that the first reproduction data is identified using pattern recognition, and determination of the second reproduction data is based on the identification of the first reproduction data.

Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to a method for thinning fruit by using the active substance metamitron and corresponding metamitron-containing fruit thinning formulations.

Abstract: The present invention relates to novel phosphonic acid formulations and to their use as slug and snail baits, and to the corresponding slug and snail baits, to a process for their preparation and to their use for controlling slugs and snails.

Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-pheny]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to a novel solid form of 4-[[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino]furan-2(5H)-one, to processes for its preparation and to its use in agrochemical preparations.

Abstract: The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of lmatinib mesylate as an intermediate for the preparation of pharmaceutical compositions.

Abstract: The present invention relates to a novel solid form of 4-[[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino]furan-2(5H)-one, to processes for its preparation and to its use in agrochemical preparations.

Abstract: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino} furan-2(5H)-one with benzoic acid, to processes for the preparation thereof and use thereof.

Abstract: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one with oxalic acid, and also to processes for preparation thereof and use.

Abstract: The invention relates to a new co-crystal of 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (I) with salicylic acid, and also to processes for preparation thereof and use thereof.

Abstract: A process for micronization of pharmaceutically active agents.